Related references
Note: Only part of the references are listed.Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
Gabriela S. Hobbs et al.
HAEMATOLOGICA (2018)
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
Gabriela S. Hobbs et al.
HAEMATOLOGICA (2018)
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Ronan T. Swords et al.
BLOOD (2018)
Getting to transplant in Hodgkin lymphoma: BVB
Leo I. Gordon
BLOOD (2018)
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Elena Crisa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Maria Kleppe et al.
CANCER CELL (2018)
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
William L. Heaton et al.
LEUKEMIA (2018)
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Shannon Elf et al.
BLOOD (2018)
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T. Kuykendall et al.
ANNALS OF HEMATOLOGY (2018)
Does ruxolitinib prolong the survival of patients with myelofibrosis?
Francisco Cervantes et al.
BLOOD (2017)
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Keith W. Pratz et al.
CLINICAL CANCER RESEARCH (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Investigational Janus kinase inhibitors in development for myelofibrosis
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
Laure Gilles et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker et al.
LANCET ONCOLOGY (2017)
Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis
T. Maekawa et al.
LEUKEMIA (2017)
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
LEUKEMIA RESEARCH (2017)
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis
Matthew Decker et al.
NATURE CELL BIOLOGY (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
Margaret Nieborowska-Skorska et al.
BLOOD (2017)
Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis
Maria Kleppe et al.
CELL STEM CELL (2017)
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Claire N. Harrison et al.
BLOOD (2017)
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I
Carole B. Miller et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
Can histologic transformation of follicular lymphoma be predicted and prevented?
Robert Kridel et al.
BLOOD (2017)
The Effect of Initial Molecular Profile on Response to Recombinant Interferon-α (rIFNα) Treatment in Early Myelofibrosis
Richard T. Silver et al.
CANCER (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target
Rebekka K. Schneider et al.
CELL STEM CELL (2017)
Efficacy of ALK5 inhibition in myelofibrosis
Lanzhu Yue et al.
JCI INSIGHT (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters
Marilyn M. Giacomini et al.
DRUG METABOLISM AND DISPOSITION (2017)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
Paola Guglielmelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Keith W. Pratz et al.
CLINICAL CANCER RESEARCH (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Claudius Klein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Srdan Verstovsek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2016)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
C. N. Harrison et al.
LEUKEMIA (2016)
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
Haifa Kathrin Al-Ali et al.
LEUKEMIA & LYMPHOMA (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Early bone marrow involvement by mantle cell lymphoma
Parker W. Clement et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
Koji Sasaki et al.
LEUKEMIA & LYMPHOMA (2015)
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen et al.
NATURE MEDICINE (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
Lucia Mazzacurati et al.
ONCOTARGET (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
Ramy A. Abdelrahman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2015)
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Neha Bhagwat et al.
BLOOD (2014)
An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin
Soraya Carrancio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
G. Barosi et al.
LEUKEMIA (2014)
Anti-transforming growth factor-β therapy in patients with myelofibrosis
John Mascarenhas et al.
LEUKEMIA & LYMPHOMA (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse
Marinos Kallikourdis et al.
BLOOD (2013)
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
Emeline Evrot et al.
CLINICAL CANCER RESEARCH (2013)
Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap
Camelia Iancu-Rubin et al.
EXPERIMENTAL HEMATOLOGY (2013)
Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms
Cristina Perez et al.
HAEMATOLOGICA (2013)
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2013)
AKT is a therapeutic target in myeloproliferative neoplasms
I. Khan et al.
LEUKEMIA (2013)
mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
Costanza Bogani et al.
PLOS ONE (2013)
Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
Sung O. Park et al.
PLOS ONE (2013)
Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
Michaela Waibel et al.
CELL REPORTS (2013)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
Alfonso Quintas-Cardama et al.
LEUKEMIA RESEARCH (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
M. Nakatake et al.
ONCOGENE (2012)
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Angela G. Fleischman et al.
BLOOD (2011)
Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Ronan T. Swords et al.
BLOOD (2010)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Share Paper
